恩扎卢胺与地高辛检测的分析干扰
本文报告两例接受恩扎卢胺治疗的患者出现地高辛血浆浓度升高(例1为4 µg/L和3.5 µg/L,例2为2.8 μg/L、D3 3 μg/L、D7 3.6 μg/L),但均无临床或生物学过量征象。例2样本用化学发光微粒子免疫分析法(CMIA®,Abbott,伊利诺伊州)检测地高辛,并用HPLC-UV/DAD法检测恩扎卢胺,血浆恩扎卢胺浓度为12.5 mg/L。向对照血浆中加入4、10、20、40 mg/L恩扎卢胺后,CMIA法检测地高辛呈阳性(0.35至3.69 µg/L)。结论提示恩扎卢胺对CMIA法地高辛检测存在分析干扰。
要点
- 接受恩扎卢胺治疗的患者中,CMIA法检测地高辛血浆浓度可出现假性升高(加入恩扎卢胺4–40 mg/L后地高辛检测值0.35–3.69 µg/L)。
- 两例患者地高辛浓度升高(例1 4 µg/L和3.5 µg/L;例2 2.8 μg/L、D3 3 μg/L、D7 3.6 μg/L)但均无临床或生物学过量征象。
- 例2血浆恩扎卢胺浓度为12.5 mg/L,提示临床可达干扰浓度范围。
- 怀疑假性升高时,应结合临床评估,避免仅凭免疫法检测结果停药。
适用人群与场景
- 接受恩扎卢胺治疗并需监测地高辛血浆浓度的患者(两例均为84岁男性)。
研究设计与关键结果
- 两例接受恩扎卢胺治疗的患者地高辛血浆浓度升高(例1:4 µg/L和3天后3.5 µg/L;例2:入院2.8 μg/L、D3 3 μg/L、D7 3.6 μg/L),但无临床或生物学过量征象。
- 例2 D7地高辛浓度在两实验室检测一致(3.5 vs. 3.6 µg/L),血浆恩扎卢胺浓度为12.5 mg/L。
- 向对照血浆中加入4、10、20、40 mg/L恩扎卢胺后,CMIA法检测地高辛呈阳性(0.35至3.69 µg/L)。
证据类型、等级与局限
- 证据类型:病例报告(两例)及体外干扰实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,恩扎卢胺对CMIA法地高辛检测存在分析干扰,可导致地高辛血浆浓度假性升高。
- 对接受恩扎卢胺的患者,地高辛浓度升高但无临床或生物学过量征象时,应考虑分析干扰的可能。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Objective: We report two cases of elevated digoxin plasma levels in patients receiving enzalutamide. Cases reported: The first patient, an 84-year-old male treated with enzalutamide, was hospitalized due to deterioration in his general state. Atrial fibrillation was discovered and treatment with digoxin was initiated. Supratherapeutic digoxin concentrations (4 µg/L and 3.5 µg/L 3 days later) led to treatment being stopped despite the lack of clinical or biological signs of overdose. The second patient, an 84-year-old male treated with digoxin and enzalutamide, was hospitalized for the same reasons. Digoxin concentration upon admission was 2.8 μg/L. Despite stopping treatment, digoxin blood levels were observed to have increased on D3 and D7 following admission (3 and 3.6 μg/L, respectively). However, no clinical or biological findings indicated an overdose. Blood samples were sent to the Pharmacology and Toxicology Laboratory for analysis. Methods: The second patient's digoxin plasma level was determined using the chemiluminescent microparticle immunoassay (CMIA®, Abbott, Illinois) method. Enzalutamide levels were determined using HPLC-UV/DAD method. An interference study was performed using different assay methods by adding enzalutamide to control plasma at various concentrations from a Xtandi® (40mg) capsule. Results: Plasma concentration of digoxin at D7 for patient 2 was identical in both laboratories (3.5 vs. 3.6 µg/L). Enzalutamide was found in the patient's plasma (12,5 mg/L). Adding 4, 10, 20, and 40 mg/L of enzalutamide to the untreated plasma showed that the plasma concentration of digoxin was positive (from 0.35 to 3.69 µg/L) using the CMIA method. Conclusions: Our results highlight the analytical interferences of enzalutamide with digoxin assays using the CMIA method.
参考来源
- Deguigne M, Brunet M, Abbara C, et al. Enzalutamide and analytical interferences in digoxin assays. Clin Toxicol (Phila). 2018. PMID: 29741399. doi:10.1080/15563650.2018.1469758
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。